Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response

Scandinavian Journal of Rheumatology

Volumn 34, Issue 3, 2005, Pages 229-232

  Omdal, Roald ^a,b   Wildhagen, K ^a   Hansen, T ^c   Gunnarsson, R ^a   Kristoffersen, G ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANEMIA; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW TOXICITY; CASE REPORT; COMPLEMENT ACTIVATION; CYTOLYSIS; DRUG PROTEIN BINDING; DRUG PULSE THERAPY; FACE PAIN; FATIGUE; HUMAN; LOW DRUG DOSE; MALAISE; MALE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 22144448927     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/02813430510015269     Document Type: Article

References (15)

1. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side effects of rituximab treatment. Br J Haematol 2001; 115:807-11.
2. Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B-cells in vivo by a chimeric mouse monoclonal antibody to CD20. Blood 1994;83:435-45.
3. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004;33:82-6.
4. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
5. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116:465-7.
6. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2673-7.
7. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;15:488-98.
8. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Vatten L, Jorstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000;15:611-18.
9. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR-3-ANCA-associated vasculitis. J Am Soc Nephrol 2002;13:2232-8.
10. Harper L, Savage COS. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000;190:349-59.
11. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalfa blockade with infliximab in anti-neutrophil cytoplasmatic antibody-associated vasculitis. J Am Soc Nephrol 2004;15:717-21.
12. Specks U, Fervenza FC, McDonald T, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
13. Popa ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Tervaert JW. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxydase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum 2002;46:1894-904.
14. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-9.
15. NIH Conference, Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Ann Intern Med 1998;129:49-58.